SRBD1 Regulates the Cell Cycle, Apoptosis, and M2 Macrophage Polarization via the RPL11‐MDM2‐p53 Pathway in Glioma
Environmental Toxicology · 2025
DOI: 10.1002/tox.24396 ↗Kurz gefasst
Fachartikel in der Zeitschrift Environmental Toxicology, 2025. Verfasst von Hongfu Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China. Hauptthemen laut MEDLINE: Ribosomal Proteins, Glioma, Proto-Oncogene Proteins c-mdm2, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Low expression of certain ribosomal proteins leads to the inactivation of p53, which is mediated mainly by RPL5 or RPL11 (ribosomal protein L11). It is also unknown what mechanisms drive aberrant ribosomal proteins expression in tumor. SRBD1 (S1 RNA‐binding domain 1), as a highly conserved RNA‐binding protein, is lowly expressed in glioma tissues and correlated with glioma prognosis. In this study, we observed that SRBD1 was closely related to p53 signaling. The upregulation of SRBD1 elevated p53 levels, thereby activating the p53 signaling pathway. As an RNA bind protein, SRBD1 could bind to the 5′‐UTR of target genes and regulate RNA translation. We further conducted RNA immunoprecipitation using anti‐SRDB1 antibody and noticed 29 hub RNA, including RPL11. RPL11 could inhibit MDM2‐mediated p53 ubiquitination. SRBD1 upregulation promoted RPL11 binding to MDM2 via elevating RPL11 protein levels, which in turn activated the p53 signaling. Disrupting the p53 signaling blocked SRBD1‐induced glioma suppression. In mouse xenograft model, SRBD1 ectopic expression was effective in reducing the total M2 tumor‐associated macrophages (TAMs) density and suppressed glioma tumor growth. In summary, these data show that SRBD1 has a critical role in inhibition of glioma tumor growth and M2 macrophage polarization, and targeting RPL11‐MDM2‐p53 signaling may be an effective strategy to improve therapy and survival for glioma patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China.
- Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.
- Department of Anesthesiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.
- Department of Neurosurgery, Rizhao Central Hospital, Rizhao, Shandong, People's Republic of China.
ORCID-Profile: Hongfu Chen, Yuechao Fan, Er Nie, Qing Lan
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
Zitieren
APA
Chen, H., Gao, S., Wang, P., Xie, M., Zhang, H., Fan, Y., Nie, E., & Lan, Q. (2025). SRBD1 Regulates the Cell Cycle, Apoptosis, and M2 Macrophage Polarization via the RPL11‐MDM2‐p53 Pathway in Glioma. Environmental Toxicology. https://doi.org/10.1002/tox.24396
Vancouver
Chen H, Gao S, Wang P, Xie M, Zhang H, Fan Y, et al. SRBD1 Regulates the Cell Cycle, Apoptosis, and M2 Macrophage Polarization via the RPL11‐MDM2‐p53 Pathway in Glioma. Environmental Toxicology. 2025. doi:10.1002/tox.24396
BibTeX
@article{Chen2025,
author = {Chen, Hongfu and Gao, Shuping and Wang, Peng and Xie, Manyi and Zhang, Hui and Fan, Yuechao and Nie, Er and Lan, Qing},
title = {SRBD1 Regulates the Cell Cycle, Apoptosis, and M2 Macrophage Polarization via the RPL11‐MDM2‐p53 Pathway in Glioma},
journal = {Environmental Toxicology},
year = {2025},
doi = {10.1002/tox.24396}
}
EUVIMED